SCHEMBL2497655

SCHEMBL2497655

N=c1n(Cc2ccccc2)c2ccccc2n1Cc1ccc(Br)cc1

nearest known ligand 0.79

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 4/20 0.79
SMN1; SMN2 Q16637 3/20 0.79
TSHR P16473 2/20 0.61
CXCR3 P49682 1/20 0.55
HTT P42858 2/20 0.55
SLC5A2 P31639 6/20 0.54
MAPT P10636 3/20 0.53
NPSR1 Q6W5P4 3/20 0.53
KMT2A Q03164 2/20 0.53
MITF O75030 1/20 0.53
OXTR P30559 1/20 0.53
AVPR1A P37288 1/20 0.53
BLM P54132 1/20 0.53
ALDH1A1 P00352 1/20 0.53
KDM4E B2RXH2 2/20 0.52
L3MBTL1 Q9Y468 1/20 0.52
GALR3 O60755 1/20 0.50
NR2F2 P24468 1/20 0.50
ALOX15 P16050 2/20 0.49
HSD17B10 Q99714 2/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1170484 0.89 LMNA (1.00) LMNASMN1; SMN2TSHRHTTSLC5A2
SCHEMBL2496126 0.85 CXCR3 (0.77) LMNASMN1; SMN2TSHRCXCR3HTT
SCHEMBL5460666 0.83 MAPT (0.69) LMNASMN1; SMN2TSHRCXCR3HTT
SCHEMBL2493570 0.83 LMNA (0.54) LMNASMN1; SMN2TSHRCXCR3HTT
SCHEMBL3207909 0.83 TP53 (0.68) LMNASMN1; SMN2TSHRCXCR3HTT
SCHEMBL2495808 0.82 MAPT (0.61) LMNASMN1; SMN2TSHRCXCR3HTT
SCHEMBL2493856 0.82 MAPT (0.64) LMNASMN1; SMN2TSHRCXCR3HTT
SCHEMBL3205881 0.81 TP53 (0.74) LMNASMN1; SMN2TSHRCXCR3HTT
SCHEMBL1170639 0.79 SLC5A2 (0.78) LMNASMN1; SMN2TSHRCXCR3HTT
SCHEMBL2475227 0.79 LMNA (0.79) LMNASMN1; SMN2TSHRHTTSLC5A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8759520-B2 Compounds for treating cancer BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2014-06-24 US disclosed
US-8759520-B2 Compounds for treating cancer BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2014-06-24 US disclosed
US-8759520-B2 Compounds for treating cancer BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2014-06-24 US disclosed
EP-2373629-B1 COMPOUNDS FOR TREATING CANCER BOEHRINGER INGELHEIM INT (DE) 2013-04-10 EP disclosed
EP-2373629-B1 COMPOUNDS FOR TREATING CANCER BOEHRINGER INGELHEIM INT (DE) 2013-04-10 EP disclosed
US-20110312969-A1 COMPOUNDS FOR TREATING CANCER BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2011-12-22 US disclosed
US-20110312969-A1 COMPOUNDS FOR TREATING CANCER BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2011-12-22 US disclosed
US-20110312969-A1 COMPOUNDS FOR TREATING CANCER BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2011-12-22 US disclosed
EP-2373629-A1 COMPOUNDS FOR TREATING CANCER BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2011-10-12 EP disclosed
WO-2010067067-A1 COMPOUNDS FOR TREATING CANCER EVOTEC AG (DE) 2010-06-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110312969-A1 COMPOUNDS FOR TREATING CANCER BCL2, BAX, BCL2A1 LMNA 2691/4885SMN1; SMN2 2259/4885TSHR 1143/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.